Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study

Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen, Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen

Abstract

Introduction: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has proven effective in reducing weight gain and insulin dose. The present publication describes a protocol for a study evaluating the efficacy and safety of adding a GLP-1RA to insulin treatment in overweight patients with T1D in a randomised, double-blinded, controlled design.

Methods and analysis: In total, 100 patients with type 1 diabetes, poor glycaemic control (glycated haemoglobin (HbA1c) >8%) and overweight (body mass index >25 kg/m(2)) will be randomised to either liraglutide 1.8 mg once daily or placebo as an add-on to intensive insulin therapy in this investigator initiated, double-blinded, placebo-controlled parallel study. The primary end point is glycaemic control as measured by changes in HbA1c. Secondary end points include changes in the insulin dose, hypoglyacemic events, body weight, lean body mass, fat mass, food preferences and adverse events. Glycaemic excursions, postprandial glucagon levels and gastric emptying rate during a standardised liquid meal test will also be studied.

Ethics and dissemination: The study is approved by the Danish Medicines Authority, the Regional Scientific-Ethical Committee of the Capital Region of Denmark and the Data Protection Agency. The study will be carried out under the surveillance and guidance of the good clinical practice (GCP) unit at Copenhagen University Hospital Bispebjerg in accordance with the ICH-GCP guidelines and the Helsinki Declaration.

Trial registration number: NCT01612468.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Flow chart of the study.

References

    1. Banting FG, Best CH. The internal secretion of the pancreas 1922. Indian J Med Res 2007;125:251–66.
    1. [No authors listed] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86. 10.1056/NEJM199309303291401
    1. Nathan DM, Cleary PA, Backlund JY et al. . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53. 10.1056/NEJMoa052187
    1. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014;37(Suppl 1):S14–80. 10.2337/dc14-S014
    1. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750–6. 10.4158/EP.14.6.750
    1. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902–12. 10.2337/diacare.26.6.1902
    1. Must A, Spadano J, Coakley EH et al. . The disease burden associated with overweight and obesity. JAMA 1999;282:1523–9. 10.1001/jama.282.16.1523
    1. Wajchenberg BL, Feitosa AC, Rassi N et al. . Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocr Pract 2008;14:912–23. 10.4158/EP.14.7.912
    1. Chillaron JJ, Flores Le-Roux JA, Benaiges D et al. . Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 2014;63:181–7. 10.1016/j.metabol.2013.10.002
    1. Inzucchi SE, Bergenstal RM, Buse JB et al. . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79. 10.2337/dc12-0413
    1. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799–812. 10.1111/j.1463-1326.2006.00686.x
    1. Eng C, Kramer CK, Zinman B et al. . Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228–34. 10.1016/S0140-6736(14)61335-0
    1. Madsbad S, Krarup T, Deacon CF et al. . Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491–9. 10.1097/MCO.0b013e328302f414
    1. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes 2011;60:1599–607. 10.2337/db10-1790
    1. Ghazi T, Rink L, Sherr JL et al. . Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014;37:210–16. 10.2337/dc13-1169
    1. Gutniak M, Orskov C, Holst JJ et al. . Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316–22. 10.1056/NEJM199205143262003
    1. Dupre J, Behme MT, Hramiak IM et al. . Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995;44:626–30. 10.2337/diab.44.6.626
    1. Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 2013;100:e55–8. 10.1016/j.diabres.2013.01.020
    1. Kielgast U, Krarup T, Holst JJ et al. . Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463–8. 10.2337/dc11-0096
    1. Kuhadiya ND, Malik R, Bellini NJ et al. . Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19:963–7. 10.4158/EP13065.OR
    1. Rother KI, Spain LM, Wesley RA et al. . Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251–7. 10.2337/dc09-0773
    1. Sarkar G, Alattar M, Brown RJ et al. . Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014;37:666–70. 10.2337/dc13-1473
    1. Varanasi A, Bellini N, Rawal D et al. . Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77–84. 10.1530/EJE-11-0330
    1. Kuhadiya N, Dhindsa S, Mehta A et al. . Liraglutide as additional treatment to insulin in patients with type 1 diabetes mellitus: a randomized clinical trial, 23rd Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE), abstract 295, 2014.
    1. TK H. NBV: Type 1 Diabetes Mellitus. Secondary NBV: Type 1 Diabetes Mellitus 2014, 2014.
    1. Bergenstal RM, Tamborlane WV, Ahmann A et al. . Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311–20. 10.1056/NEJMoa1002853
    1. Li L, Shen J, Bala MM et al. . Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366 10.1136/bmj.g2366
    1. Madsbad S. Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes. Diabetologia 1983;24:141–7.
    1. Unger RH, Aguilar-Parada E, Muller WA et al. . Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970;49:837–48. 10.1172/JCI106297
    1. Nauck MA, Kemmeries G, Holst JJ et al. . Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011;60:1561–5. 10.2337/db10-0474

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する